name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in plasma from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in plasma from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in serum from capillary blood, quantitative report with steady-state range for prescribed drug when detected


name: Measurement of single oral oncology substance by definitive tandem mass spectrometry with chromatography, in serum from venous blood, quantitative report with steady-state range for prescribed drug when detected


name: Targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis of colon cells for colon cancer in formalin-fixed paraffin-embedded tissue


name: Detection and identification of infectious agent by targeted gene sequence analysis (16S and 18S rRNA genes) with drug-resistance gene


name: Enzyme immunoassay of 35 or more drugs confirmed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications


name: Analysis of 11 endogenous agents (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid [3-HPMA], quinolinic acid, kynurenic acid), by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in urine, algorithm reported as pain-index score with likelihood of atypical biochemical function associated with pain


name: Measurement of ceramides by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in plasma, quantitative report with risk score for major cardiovascular events


name: Vacuum cell adhesion molecule (VCAM-1) microfluidic flow adhesion test in whole blood for sickle cell disease


name: Red blood cell (RBC) mechanical fragility test with shear stress and spectral analysis profiling


name: Hereditary breast cancer-related disorders genomic sequence analysis for detection of deletion and duplication analysis panel (including ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)


name: Hereditary colon cancer disorders targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53)


name: Hereditary ovarian cancer-related disorders targeted mRNA sequence analysis panel of 17 genes


name: Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel of 11 genes


name: Hereditary pan cancer targeted mRNA sequence analysis panel including 18 genes


name: Hereditary gynecological cancer-related disorders targeted mRNA sequence analysis panel of 12 genes


name: Partner and localizer of BRCA2 (PALB2) mRNA sequence analysis


name: BRCA1, (BRAC1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) mRNA sequence analysis


name: Amplifed DNA probe detection of fungus in blood culture specimen


name: Identification of fungal pathogen in blood culture specimen by DNA amplified probe technique, 15 fungal targets, reported as detected or not detected


name: Amplifed DNA probe detection of 20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, and 1 pan Candida target in blood culture specimen


name: Identification of gram-positive organism and detection of drug resistance element in blood culture specimen by DNA amplified probe technique, 20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target, reported as detected or not detected


name: Amplifed DNA probe detection of 20 gram-positive bacterial targets, 6 resistance genes, 1 pan gram-negative bacterial target, and 1 pan Candida target in blood culture specimen


name: Identification of gram-positive organism and detection of drug resistance element in blood culture by DNA amplified probe technique, 21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target, reported as detected or not detected


name: mRNA gene expression profiling of 101 genes in breast growth tissue specimen


name: mRNA gene expression profiling of breast cancer by real-time polymerase chain reaction (RT-PCR) and next-generation sequencing of 101 genes, algorithm reported as triple negative breast cancer clinical subtype with information on immune cell involvement


name: Oncology (urothelial cancer), RNA, analysis by real-time RT-PCR of the FGFR3 (fibroblast growth factor receptor 3) gene analysis (ie, p.R248C [c.742C>T], p.S249C [c.746C>G], p.G370C [c.1108G>T], p.Y373C [c.1118A>G], FGFR3-TACC3v1, and FGFR3-TACC3v3), utilizing formalin-fixed paraffin-embedded urothelial cancer tumor tissue, reported as FGFR gene alteration status


name: RNA gene analysis for detection of fibroblast growth factor receptor 3 gene alteration in urothelial tumor tissue specimen


name: RNA analysis of urothelial cancer by real-time polymerase chain reaction (RT-PCR) of fibroblast growth factor receptor 3 (FGFR3) gene, reported as FGFR gene alteration status


name: Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) (eg, breast cancer) gene analysis (ie, p.C420R, p.E542K, p.E545A, p.E545D [g.1635G>T only], p.E545G, p.E545K, p.Q546E, p.Q546R, p.H1047L, p.H1047R, p.H1047Y), utilizing formalin-fixed paraffin-embedded breast tumor tissue, reported as PIK3CA gene mutation status


name: DNA analysis for detection of PIK3CA gene mutation in breast growth tissue specimen


name: DNA analysis of breast cancer by phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene analysis, reported as PIK3CA gene mutation status


name: Gene analysis copy number sequence analysis


name: mRNA gene analysis of APC regulator of WNT signaling pathway


name: APC regulator of WNT signaling pathway (APC) mRNA sequence analysis


name: MutL homolog 1 (MLH1) mRNA sequence analysis


name: MutS homolog 2 (MSH2) mRNA sequence analysis


name: MutS homolog 6 (MSH6) mRNA sequence analysis


name: mRNA gene analysis of PMS1 homolog 2, mismatch repair system component


name: PMS1 homolog 2 (PMS2 mismatch repair system component) mRNA sequence analysis


name: Targeted mRNA sequence analysis for genes associated with hereditary colon cancer


name: MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6), and PMS1 homolog 2 (PMS2 mismatch repair system component) targeted mRNA sequence analysis panel


name: Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas


name: Screening test for 3 protein biomarkers of colorectal cancer in serum or plasma specimen


name: Screening for colorectal cancer by biochemical enzyme-linked immunosorbent assay (ELISA) of teratocarcinoma derived growth factor-1 (TDGF-1, Cripto-1), carcinoembryonic antigen (CEA), and extracellular matrix protein (ECM), with demographic data, algorithm reported as likelihood of colorectal cancer or advanced adenomas


name: Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results


name: Test for detection of antibodies associated with irritable bowel syndrome in plasma specimen, reported as elevated or not elevated


name: Immunoassay for inflammatory bowel-associated antibodies anti-cytolethal distending toxin B (CdtB) and anti-vinculin antibodies in plasma specimen, algorithm reported as elevated or not elevated


name: Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy


name: Test for detection of antigens associated with peanut allergy in blood specimen, reported as probability of peanut allergy


name: Measurement of multiple peanut allergen-specific epitopes in blood specimen by enzyme-linked immunosorbent assay (ELISA), reported as individual epitope results and probability of peanut allergy


name: Liver disease, 10 biochemical assays (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation


name: Liver disease test panel in serum specimen


name: Biochemical assay for 10 markers of liver disease (α2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, gamma-glutamyl transferase [GGT], alanine aminotransferase [ALT], aspartate aminotransferase [AST], triglycerides, cholesterol, and fasting glucose) in serum specimen, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with summary interpretation


name: NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants


name: Gene analysis (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) for detection of common variants


name: Nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) gene analysis for detection of common variants


name: Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis


name: RNA gene sequencing for probability of autism spectrum disorder in saliva specimen


name: Next-generation RNA sequencing of genes associated with autism spectrum disorder in saliva specimen, algorithm reported as predictive probability of autism spectrum disorder


name: Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence


name: DNA analysis of targeted sequences in 23 genes for detection of abnormalites associated with myeloid leukemia, myelodysplastic syndrome, and myeloproliferative cancer


name: Targeted DNA sequence analysis panel of 23 genes for detection of abnormalities associated with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, reported as presence/absence


name: Oncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) and analysis of homologous recombination deficiency pathways, DNA, formalin-fixed paraffin-embedded tissue, algorithm quantifying tumor genomic instability score


name: DNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair associated) for detection of mutations associated with breast cancer


name: Somatic mutation analysis of BRCA1, DNA repair associated (BRCA1) and BRCA2 (BRCA2, DNA repair associated) and DNA analysis of homologous recombination deficiency pathways in breast tumor tissue specimen, algorithm reported as tumor genomic instability score


name: Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes


name: Gene analysis panel for detection of variants in 14 genes associated with psychiatric disorders


name: Genomic analysis panel of 14 genes for detection of variants associated with psychiatric disorder


name: Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents


name: Mass spectrometry testing for 30 protein targets in tissue specimen to predict benefit of cancer therapy agents


name: Evaluation of 30 protein targets in tumor tissue specimen by mass spectometry, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents


name: Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes


name: Gene analysis panel for detection of variants in 15 genes associated with psychiatric disorders


name: Genomic analysis panel of 15 genes for detection of variants associated with psychiatric disorder


name: Test for detection of IgG antibodies associated with irritable bowel syndrome


name: Oncology (breast cancer), DNA, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis of 11 gene variants utilizing plasma, reported as PIK3CA gene mutation status


name: DNA gene analysis (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) for detection of mutations associated with breast cancer


name: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) DNA gene analysis of 11 gene variants in plasma specimen, reported as PIK3CA gene mutation status


name: Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction


name: Test for detection of antigens associated with peanut allergy in blood specimen, reported as minimum exposure for clinical reaction


name: Measurement of multiple peanut allergen-specific epitopes by enzyme-linked immunosorbent assay (ELISA) in blood specimen, report of minimum eliciting exposure for clinical reaction


name: Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)


name: Cell-free DNA analysis of targeted sequences in 23 genes for detection of mutations associated with non-small cell lung cancer


name: Targeted sequence analysis of 23 genes in cell-free DNA specimen for significant mutation


name: Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons


name: Red blood cell antigen genotyping, ABO blood group


name: ABO blood group red cell antigen genotyping, ABO alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) Sanger/chain termination/conventional sequencing of 7 exons, including subtyping


name: Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1


name: Red blood cell antigen genotyping, Colton blood group


name: Colton blood group red cell antigen genotyping (CO), aquaporin 1 (Colton blood group) (AQP1) gene analysis of exon 1


name: Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10


name: Red blood cell antigen genotyping, CD55 molecule [Cromer blood group] exons 1-10


name: Cromer blood group red cell antigen genotyping (CROM), CD55 molecule (Cromer blood group) (CD55) gene analysis of exons 1-10


name: Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19


name: Red blood cell antigen genotyping, solute carrier family 4 member 1 [Diego blood group] exon 19


name: Diego blood group red cell antigen genotyping (DI), solute carrier family 4 member 1 (Diego blood group) (SLC4A1) gene analysis of exon 19


name: Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2


name: Red blood cell antigen genotyping, ADP-ribosyltransferase 4 [Dombrock blood group] exon 2


name: Dombrock blood group red cell antigen genotyping (DO), ADP-ribosyltransferase 4 (Dombrock blood group) (ART4) gene analysis of exon 2


name: Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4


name: Red blood cell antigen genotyping, fucosyltransferase 1 [H blood group] exon 4


name: H blood group red cell antigen genotyping (FUT1), fucosyltransferase 1 (H blood group) (FUT1) gene analysis of exon 4


name: Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2


name: Red blood cell antigen genotyping, fucosyltransferase 2 [H blood group] exon 2


name: H blood group red cell antigen genotyping (FUT2), fucosyltransferase 2 (H blood group) (FUT2) gene analysis of exon 2


name: Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2


name: Red blood cell antigen genotyping, atypical chemokine receptor 1 [Duffy blood group] exons 1-2


name: Duffy blood group red cell antigen genotyping (FY), atypical chemokine receptor 1 (Duffy blood group) (ACKR1) gene analysis of exons 1-2


name: Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4


name: Red blood cell antigen genotyping, glycophorin C [Gerbich blood group] exons 1-4


name: Gerbich blood group red cell antigen genotyping (GE), glycophorin C (Gerbich blood group) (GYPC) gene analysis of exons 1-4


name: Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2


name: Red blood cell antigen genotyping, glycophorin A [MNS blood group] introns 1, 5, exon 2


name: MNS blood group blood group red cell antigen genotyping (GYPA), glycophorin A (MNS blood group) (GYPA) gene analysis of introns 1, 5, exon 2


name: Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3


name: Red blood cell antigen genotyping, glycophorin B [MNS blood group] introns 1, 5, pseudoexon 3


name: MNS blood group blood group red cell antigen genotyping (GYPB), glycophorin B (MNS blood group) (GYPB) gene analysis of introns 1, 5, pseudoexon 3


name: Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6


name: Red blood cell antigen genotyping, CD44 molecule [Indian blood group] exons 2, 3, 6


name: Indian blood group red cell antigen genotyping (IN), CD44 molecule (Indian blood group) (CD44) gene analysis of exons 2, 3, 6


name: Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9


name: Red blood cell antigen genotyping, solute carrier family 14 member 1 [Kidd blood group] gene promoter, exon 9solute carrier family 14 member 1 [Kidd blood group] gene promoter, exon 9


name: Kidd blood group red cell antigen genotyping (JK), solute carrier family 14 member 1 (Kidd blood group) (SLC14A1) gene analysis of exon 9


name: Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26


name: Red blood cell antigen genotyping, ATP binding cassette subfamily G member 2 [Junior blood group] exons 2-26


name: JR blood group red cell antigen genotyping (JR), ATP binding cassette subfamily G member 2 (Junior blood group) (ABCG2) gene analysis of exons 2-26


name: Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8


name: Red blood cell antigen genotyping, Kell metallo-endopeptidase [Kell blood group] exon 8


name: Kell blood group red cell antigen genotyping (KEL), Kell metallo-endopeptidase (Kell blood group) (KEL) gene analysis of exon 8


name: KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)


name: Gene analysis (Kruppel-like factor 1) targeted sequence analysis


name: Kruppel-like factor 1 (KLF1) gene analysis of targeted sequence


name: Kruppel-like factor 1 (KLF1) targeted sequence analysis of exon 13


name: Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3


name: Red blood cell antigen genotyping, basal cell adhesion molecule [Lutheran blood group] exon 3


name: Lutheran blood group red cell antigen genotyping (LU), basal cell adhesion molecule (Lutheran blood group) (BCAM) gene analysis of exon 3


name: Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1


name: Red blood cell antigen genotyping, intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]


name: Landsteiner-Wiener blood group red cell antigen genotyping (LW), intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) (ICAM4) gene analysis of exon 1


name: Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5


name: Red blood cell antigen genotyping, Rh blood group D antigen exons 1-10 and Rh blood group CcEe antigens exon 5


name: RH blood group red cell antigen genotyping (RHD and RHCE), Rh blood group D antigen (RHD) Sanger/chain termination/conventional sequencing of exons 1-10 and Rh blood group CcEe antigens (RHCE) exon 5


name: Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12


name: Red blood cell antigen genotyping, erythroblast membrane associated protein [Scianna blood group] exons 4, 12


name: Scianna blood group red cell antigen genotyping (SC), erythroblast membrane associated protein (Scianna blood group) (ERMAP) gene analysis of exons 4, 12


name: Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3


name: Red blood cell antigen genotyping, X-linked Kx blood group exons 1-3


name: Kx blood group red cell antigen genotyping (XK), X-linked Kx blood group) (XK) gene analysis of exons 1-3


name: Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2


name: Red blood cell antigen genotyping, acetylcholinesterase [Cartwright blood group] exon 2


name: Yt blood group red cell antigen genotyping (YT), (Acetylcholinesterase (Cartwright blood group) (ACHE) gene analysis of exon 2


name: Test for detection of respiratory disease-causing organisms from back of nose and throat (nasopharynx) specimen, 22 target organisms including severe acute respiratory syndrome coronavirus 2


name: Detection of pathogen-specific nucleic acid in nasopharyngeal swab specimen by qualitative real-time polymerase chain reaction (RT-PCR), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), each pathogen reported as detected or not detected


name: Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness


name: mRNA gene expression profiling of 17 genes in whole blood specimen for evaluation of inflammatory bowel disease


name: mRNA gene expression profiling by quantitative real-time polymerase chain reaction (RT-PCR), 17 genes (15 target and 2 reference genes) in whole blood specimen, reported as continuous risk score and classification of inflammatory bowel disease aggressiveness


name: Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements


name: Gene analysis for detection of variants in 3 genes in cheek swab specimen for neovascular age-related macular-degeneration risk associated with zinc supplements


name: Gene analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using polymerase chain reaction (PCR) and matrix-assisted laser desorption ionization time of flight (MALDI-TOF) in buccal swab specimen, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements


name: Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease


name: Cell aggregation testing of cultured skin cells for Alzheimer disease, reported as positive or negative for Alzheimer disease


name: Cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by enzyme-linked immunosorbent assay (ELISA), in cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease


name: Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)


name: Immunofluorescence testing of cultured skin cells for Alzheimer disease, reported as probability index for Alzheimer disease


name: Quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as probability index for Alzheimer disease


name: Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities


name: Cytogenomic analysis of whole genome for abnormal chromosomes


name: Cytogenomic constitutional analysis with interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities


name: Syphilis test, non-treponemal antibody, immunoassay, quantitative (RPR)


name: Measurement of nontreponemal antibodies associated with syphilis


name: Syphilis test by detection of non-treponemal antibody by immunoassay using rapid plasma reagin (RPR)


name: Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association


name: Next-generation sequencing of DNA and RNA in tumor tissue specimen with interpretative report


name: Next-generation DNA and RNA sequencing in tissue specimen, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association


name: Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband


name: Rare diseases genetic testing of complete DNA of first affected person in family


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from proband


name: Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling)


name: Rare diseases genetic testing of complete DNA of relative of affected person in family


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator blood sample from parent of proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator blood sample from relative of proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator blood sample from sibling of proband


name: Whole genome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in comparator saliva sample from relative of proband


name: Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband


name: Rare diseases genetic testing of protein coding genes of first affected person in family


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from proband


name: Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)


name: Rare diseases genetic testing of protein coding genes of relative of affected person in family


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from parent of proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood sample from relative of proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from parent of proband


name: Whole exome and mitochondrial DNA sequence analysis for rare disease, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva sample from relative of proband


name: Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants


name: DNA analysis of gene sequence of 12 genes for identification and characterization of abnormalites associated with inherited disorders of movement (ataxia)


name: Genomic DNA sequence of 12 common genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood specimen, with identification and categorization of genetic variants


name: Genomic DNA sequence of 12 common genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva specimen, with identification and categorization of genetic variants


name: Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants


name: DNA analysis of gene sequence of 51 genes for identification and characterization of abnormalites associated with inherited disorders of movement (ataxia)


name: Genomic DNA sequence of 51 genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood specimen, with identification and categorization of genetic variants


name: Genomic DNA sequence of 51 genes associated with inherited ataxia, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva specimen, with identification and categorization of genetic variants


name: Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants


name: DNA analysis of gene sequence for identification and characterization of abnormalites associated with muscular dystrophy


name: Duschenne muscular dystrophy (DMD gene sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in blood specimen, with identification and categorization of genetic variants


name: Duschenne muscular dystrophy (DMD gene sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, in saliva specimen, with identification and categorization of genetic variants


name: Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility


name: Gene analysis of human immunodeficiency virus targeted sequence analysis for resistance to antiviral drugs


name: Targeted next-generation protease (PR), reverse transcriptase (RT), integrase (INT) sequence analysis of human immunodeficiency virus, algorithm reported as prediction of antiviral drug susceptibility


name: Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score


name: Image analysis of breast cancer cell specimen with artificial intelligence assessment


name: Image analysis of breast cancer with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as recurrence score


name: Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene


name: Red blood cell antigen genotyping, ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase gene next generation sequencing


name: ABO blood group red cell antigen genotyping, ABO alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) next-generation sequencing


name: Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3


name: Red blood cell antigen genotyping, RH proximal promoter, exons 1-10, portions of introns 2-3


name: RH blood group red cell antigen genotyping (RHD and RHCE), next-generation sequencing of RH proximal promoter, exons 1-10, portions of introns 2-3


name: Detection of respiratory tract pathogen nucleic acid in nasopharyngeal swab specimen by qualitative real-time polymerase chain reaction (TR-PCR), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), each pathogen reported as detected or not detected


name: Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), includes titer(s), when performed


name: Measurement of antibody to severe acute respiratory syndrome coronavirus 2 (COVID-19)


name: Measurement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody, including titers


name: Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected


name: Test for detection of respiratory disease-causing organisms, 21 target organisms including severe acute respiratory syndrome coronavirus 2 (COVID-19)


name: Detection of respiratory disease infectious agent DNA and RNA, 21 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by amplified probe technique with multiplex reverse transcription for RNA targets, reported as detected or not detected


name: Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), ELISA, plasma, serum


name: Surrogate viral neutralization test (sVNT) for detection of antibodies to severe acute respiratory syndrome coronavirus 2 (Covid-19) by


name: Surrogate viral neutralization test (sVNT) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in plasma specimen by enzyme-linked immunosorbent assay (ELISA)


name: Surrogate viral neutralization test (sVNT) for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in serum specimen by enzyme-linked immunosorbent assay (ELISA)


name: Administration of first or only component of each toxoid via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of first or only component of each toxoid via any route with counseling by physician, patient 18 years of age or younger


name: Administration of first or only component of each vaccine via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of first or only component of each vaccine via any route with counseling by physician, patient 18 years of age or younger


name: Administration of each additional toxoid component via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of each additional toxoid component via any route with counseling by physician, patient 18 years of age or younger


name: Administration of each additional vaccine component via any route with counseling by other qualified health care professional, patient 18 years of age or younger


name: Administration of each additional vaccine component via any route with counseling by physician, patient 18 years of age or younger


name: Intranasal administration of each additional combination toxoid


name: Intranasal administration of each additional combination vaccine


name: Intranasal administration of each additional single toxoid


name: Intranasal administration of each additional single vaccine


name: Intraoral administration of each additional combination toxoid


name: Intraoral administration of each additional combination vaccine


name: Intraoral administration of each additional single toxoid


name: Intraoral administration of each additional single vaccine


name: Adenovirus vaccine, type 4, live, for oral use (procedure)


name: Adenovirus vaccine, type 7, live, for oral use (procedure)


name: Live Bacillus Calmette-Guerin (BCG) vaccine, for percutaneous use


name: Live Bacillus Calmette-Guerin (BCG) vaccine, for intravesical use


name: Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 dose schedule, for intramuscular use


name: Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 3 dose schedule, for intramuscular use


name: Cholera vaccine, adult dosage, single dose schedule, for oral use


name: Hepatitis A (HepA) vaccine, adolescent dosage, 2 dose schedule, for intramuscular use


name: Hepatitis A (HepA) vaccine, pediatric dosage, 2 dose schedule, for intramuscular use


name: Hepatitis A (HepA) vaccine, adolescent dosage, 3 dose schedule, for intramuscular use


name: Hepatitis A (HepA) vaccine, pediatric dosage, 3 dose schedule, for intramuscular use


name: Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58, nonavalent (9vHPV), 2 dose schedule, for intramuscular use


name: Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58, nonavalent (9vHPV), 3 dose schedule, for intramuscular use


name: Inactivated adjuvanted influenza virus vaccine(IIV), for intramuscular use


name: Influenza vaccine, quadrivalent for nasal administration


name: Live preservative-free influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, for intramuscular use


name: Diphtheria and tetanus (DT) toxoids adsorbed, patient younger than 7 years of age, for intramuscular use


name: Inactivated poliovirus vaccine (IPV), for intramuscular use


name: Inactivated poliovirus vaccine (IPV), for subcutaneous use


name: Preservative free tetanus and diphtheria (Td) adsorbed toxoids, patient 7 years of age or older, for intramuscular use


name: Diphtheria, tetanus toxoids, and acellular pertussis (Tdap) vaccine, patient 7 years of age or older


name: Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, patient 2 years of age or older, for intramuscular use


name: Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, patient 2 years of age or older, for subcutaneous use


name: Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 quadrivalent (MCV4 or MenACWY), for intramuscular use


name: Hepatitis B (HepB) vaccine, dialysis patient dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, immunosuppressed patient dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, adolescent dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, pediatric dosage, 3 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, dialysis patient dosage, 4 dose schedule, for intramuscular use


name: Hepatitis B (HepB) vaccine, immunosuppressed patient dosage, 4 dose schedule, for intramuscular use


name: Psychotherapy with evaluation and management visit, 45 minutes


name: Psychotherapy for crisis, each additional 30 minutes


name: Family psychotherapy with patient present, 50 minutes


name: Pharmacological management with prescription and review of medication, and psychotherapy service


name: Narcosynthesis for psychiatric diagnostic and therapeutic purposes


name: Initial delivery and management of therapeutic repetitive transcranial magnetic stimulation (TMS) treatment with cortical mapping and motor threshold determination


name: Subsequent delivery and management of therapeutic repetitive transcranial magnetic stimulation (TMS) treatment, per session


name: Subsequent motor threshold redetermination with delivery and management of therapeutic repetitive transcranial magnetic stimulation (TMS) treatment


name: Individual psychophysiological therapy incorporating biofeedback training by any modality, face-to-face with the patient, with psychotherapy, 30 minutes


name: Individual psychophysiological therapy incorporating biofeedback training by any modality, face-to-face with the patient, with psychotherapy, 45 minutes


name: Biofeedback training of anorectal sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG), initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG), initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter with manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG) and manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG) and manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG), initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG), initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles with manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of perineal muscles, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG) and manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG), initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG), initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter with manometry, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with manometry, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of urethral sphincter, initial 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter, initial 15 minutes of one-on-one physician contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG) and manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with electromyography (EMG), each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter with manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of anorectal sphincter, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG) and manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with electromyography (EMG), each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles with manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of perineal muscles, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with electromyography (EMG), each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter with with electromyography (EMG) and manometry, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Biofeedback training of urethral sphincter, each additional 15 minutes of one-on-one other qualified health care professional contact with patient


name: Hemodialysis procedure with single evaluation by other qualified health care professional


name: Dialysis procedure (other than hemodialysis) with single evaluation by other qualified health care professional


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age, with single face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age, with single face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age, with 1 face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older, with 4 or more face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older, with 2-3 face-to-face visits per month


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older, with single face-to-face visit per month


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient younger than 2 years of age


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 2-11 years of age


name: End-stage renal disease (ESRD) related monthly services with monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents, patient 12-19 years of age


name: End-stage renal disease (ESRD) related monthly services, patient 20 years of age or older


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient younger than 2 years of age


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient 2-11 years of age


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient 12-19 years of age


name: End-stage renal disease (ESRD) related services less than a full month of service, per day, patient 20 years of age or older


name: Dialysis training including helper, completed course


name: Dialysis training including helper, course not completed


name: Gastroesophageal junction study with perfusion, with interpretation and report


name: Gastroesophageal junction study with stimulation, with interpretation and report


name: Manometric study of the esophagus and gastroesophageal junction study with perfusion, with interpretation and report


name: Manometric study of the esophagus and gastroesophageal junction study with stimulation, with interpretation and report


name: Manometric study of the esophagus with perfusion, with interpretation and report


name: Manometric study of the esophagus with stimulation, with interpretation and report


name: Prolonged (more than 1 hour, less than 24 hours) gastroesophageal reflux test of esophagus with nasal catheter intraluminal impedance electrodes placement, recording, analysis and interpretation


name: Diagnostic esophageal balloon distension provocation study


name: Diagnostic esophageal balloon distension study


name: Intraluminal gastrointestinal tract imaging of esophagus through ileum, with interpretation and report


name: Intraluminal gastrointestinal tract imaging of esophagus with interpretation and report


name: Gastrointestinal tract transit and pressure measurement from stomach to colon using wireless capsule with interpretation and report


name: Colon manometric study with provocation tests, minimum of 6 hours continuous reading with interpretation and report


name: New patient ophthalmological intermediate medical examination and evaluation with initiation of diagnostic and treatment program


name: Ophthalmological comprehensive medical examination and initiation of diagnostic and treatment program for new patient, multiple visits


name: Ophthalmological comprehensive medical examination and initiation of diagnostic and treatment program for new patient, single visit


name: Ophthalmological intermediate medical examination and continuation of diagnostic and treatment program for established patient


name: Ophthalmological comprehensive medical examination with continuation of diagnostic and treatment program for established patient, multiple visits


name: Ophthalmological comprehensive medical examination with continuation of diagnostic and treatment program for established patient, single visit


name: Ophthalmological comprehensive medical examination with initiation of diagnostic and treatment program for established patient, multiple visits


name: Ophthalmological comprehensive medical examination with initiation of diagnostic and treatment program for established patient, single visit


name: Complete ophthalmological examination and evaluation under general anesthesia


name: Complete ophthalmological examination and evaluation under general anesthesia with manipulation of globe for passive range of motion to facilitate diagnostic examination


name: Complete ophthalmological examination and evaluation under general anesthesia with other manipulation to facilitate diagnostic examination


name: Limited ophthalmological examination and evaluation under general anesthesia


name: Limited ophthalmological examination and evaluation under general anesthesia with manipulation of globe for passive range of motion to facilitate diagnostic examination


name: Limited ophthalmological examination and evaluation under general anesthesia with other manipulation to facilitate diagnostic examination


name: Initial fitting of contact lens for management of keratoconus


name: Limited bilateral visual field examination with interpretation and report


name: Limited unilateral visual field examination with interpretation and report


name: Intermediate bilateral visual field examination with interpretation and report


name: Intermediate unilateral visual field examination with interpretation and report


name: Extended bilateral visual field examination with interpretation and report


name: Extended unilateral visual field examination with interpretation and report


name: Serial tonometry with multiple measurements of intraocular pressure over an extended time period on the same day with interpretation and report


name: Imaging of retina for detection or monitoring of disease


name: Bilateral imaging of retina for detection of disease with remote clinical staff review and report


name: Bilateral imaging of retina for monitoring of disease with remote clinical staff review and report


name: Unilateral imaging of retina for detection of disease with remote clinical staff review and report


name: Unilateral imaging of retina for monitoring of disease with remote clinical staff review and report


name: Bilateral imaging of retina for detection of active renal disease with remote healthcare professional review, interpretation, and report


name: Bilateral imaging of retina for monitoring of active renal disease with remote healthcare professional review, interpretation, and report


name: Unilateral imaging of retina for detection of active renal disease with remote healthcare professional review, interpretation, and report


name: Unilateral imaging of retina for monitoring of active renal disease with remote healthcare professional review, interpretation, and report


name: Imaging of retina for detection or monitoring of disease; point-of-care autonomous analysis and report, unilateral or bilateral


name: Imaging of retina for disease detection, with automated review and report at point of care


name: Bilateral fluorescein angiography with multiframe imaging, interpretation, and report


name: Unilateral fluorescein angiography with multiframe imaging, interpretation, and report


name: Bilateral indocyanine-green angiography with multiframe imaging, interpretation, and report


name: Unilateral indocyanine-green angiography with multiframe imaging, interpretation, and report


name: Bilateral fluorescein and indocyanine-green angiography with multiframe imaging, interpretation, and report


name: Unilateral fluorescein and indocyanine-green angiography with multiframe imaging, interpretation, and report


name: Needle oculoelectromyography extraocular muscles of both eyes with interpretation and report


name: Needle oculoelectromyography extraocular muscles of single eye with interpretation and report


name: Full field electroretinography (ERG) with interpretation and report


name: Multifocal electroretinography (mfERG) with interpretation and report


name: External ocular photography with interpretation and report for documentation of medical progress


name: Anterior segment imaging with specular microscopy and endothelial cell analysis with interpretation and report


name: Anterior segment imaging with fluorescein angiography with interpretation and report


name: Prescription of optical and physical characteristics of and fitting of corneal contact lens, both eyes, with medical supervision of adaptation


name: Prescription of optical and physical characteristics of and fitting of corneal contact lens for aphakia, single eye, with medical supervision of adaptation


name: Prescription of optical and physical characteristics of and fitting of corneal contact lens for aphakia, both eyes, with medical supervision of adaptation


name: Prescription of optical and physical characteristics of and fitting of corneoscleral contact lens, with medical supervision of adaptation


name: Prescription of optical and physical characteristics of and fitting of corneal contact lens, both eyes, with medical supervision of adaptation and direction of fitting by independent technician


name: Prescription of optical and physical characteristics of and fitting of corneal contact lens for aphakia, single eye, with medical supervision of adaptation and direction of fitting by independent technician


name: Prescription of optical and physical characteristics of and fitting of corneal contact lens for aphakia, both eyes, with medical supervision of adaptation and direction of fitting by independent technician


name: Prescription of optical and physical characteristics of and fitting of corneoscleral contact lens, with medical supervision of adaptation and direction of fitting by independent technician


name: fitting multifocal spectacles, except for aphakia


name: Fitting of multifocal spectacles (other than bifocal)


name: fitting monofocal spectacles for aphakia


name: fitting multifocal spectacles for aphakia


name: Fitting of single element system spectacle prosthesis


name: Fitting of compound lens system spectacle aid


name: Repair and refitting spectacles for aphakia


name: Treatment of auditory processing disorder for individual


name: Treatment of speech, language, voice, and communication disorder for individual


name: Treatment of speech, language, voice, communication, and auditory processing disorder for individual


name: Treatment of auditory processing disorder for multiple individuals


name: Treatment of speech, language, voice, and communication disorder for multiple individuals


name: Treatment of speech, language, voice, communication, and auditory processing disorder for multiple individuals


name: Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report


name: Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP)


name: VEMP testing of lower branch of inner ear nerve with interpretation and report


name: Cervical vestibular evoked myogenic potential (cVEMP) testing, with interpretation and report


name: Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; ocular (oVEMP)


name: VEMP testing of upper branch of inner ear nerve with interpretation and report


name: Ocular vestibular evoked myogenic potential (oVEMP) testing, with interpretation and report


name: Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) and ocular (oVEMP)


name: VEMP testing of upper and lower branches of inner ear nerve with interpretation and report


name: Cervical and ocular vestibular evoked myogenic potential (cVEMP and oVEMP) testing, with interpretation and report


name: Bilateral bithermal caloric vestibular test with recording


name: Bilateral monothermal caloric vestibular test with recording


name: Basic vestibular evaluation with oscillating tracking test with recording


name: Basic vestibular evaluation with spontaneous nystagmus test with recording


name: Spontaneous nystagmus test with recording


name: Bidirectional foveal stimulation optokinetic nystagmus test with recording


name: Bidirectional peripheral stimulation optokinetic nystagmus test with recording


name: Computerized dynamic posturography sensory organization test (CDP-SOT) for 6 conditions, with interpretation and report


name: Computerized dynamic posturography sensory organization test (CDP-SOT) for 6 conditions, with motor control test and adaptation test, with interpretation and report


name: Caloric vestibular test, each irrigation


name: Automated evoked otoacoustic emissions screening


name: Acoustic immittance testing with tympanometry, acoustic reflex threshold testing, and acoustic reflex decay testing


name: Limited evaluation of distortion product evoked otoacoustic emissions with interpretation and report


name: Transient evoked otoacoustic emissions with interpretation and report


name: Comprehensive diagnostic evaluation of distortion product evoked otoacoustic emissions, with interpretation and report


name: Auditory evoked potentials; screening of auditory potential with broadband stimuli, automated analysis


name: Screening evaluation of brain response to sound with automated analysis


name: Auditory evoked potentials using broadband stimuli for screening of auditory potential, with automated analysis


name: Auditory evoked potentials; for hearing status determination, broadband stimuli, with interpretation and report


name: Evaluation of brain response to sound for determination of hearing status with interpretation and report


name: Auditory evoked potentials using broadband stimuli for hearing status determination, with interpretation and report


name: Auditory evoked potentials; for threshold estimation at multiple frequencies, with interpretation and report


name: Evaluation of brain response to sound for determination of hearing threshold with interpretation and report


name: Auditory evoked potentials for threshold estimation at multiple frequencies, with interpretation and report


name: Auditory evoked potentials; neurodiagnostic, with interpretation and report


name: Evaluation of brain response to sound for diagnosis of nervous system disorders with interpretation and report


name: Diagnostic analysis of cochlear implant with programming, patient younger than 7 years of age


name: Diagnostic analysis of cochlear implant with subsequent programming, patient younger than 7 years of age


name: Diagnostic analysis of cochlear implant with programming, patient 7 years of age or older


name: Diagnostic analysis of cochlear implant with subsequent programming, patient 7 years of age or older


name: Evaluation for prescription of nonspeech-generating augmentative and alternative communication device, face-to-face with patient, first hour


name: Evaluation for prescription of nonspeech-generating augmentative and alternative communication device, face-to-face with patient, each additional 30 minutes


name: Therapeutic services for the use of non-speech-generating device with programming and modification


name: Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with patient, first hour


name: Evaluation for prescription for speech-generating augmentative and alternative communication device, face-to-face with patient, each additional 30 minutes


name: Therapeutic services for the use of speech-generating device with programming and modification


name: Flexible endoscopic evaluation of swallowing by cine recording


name: Flexible endoscopic evaluation of swallowing by video recording


name: Interpretation and report only of flexible endoscopic evaluation of swallowing by cine recording


name: Interpretation and report only of flexible endoscopic evaluation of swallowing by video recording


name: Flexible endoscopic evaluation, laryngeal sensory testing by cine recording


name: Flexible endoscopic evaluation, laryngeal sensory testing by video recording


name: Interpretation and report only of flexible endoscopic evaluation, laryngeal sensory testing by cine recording


name: Interpretation and report only of flexible endoscopic evaluation, laryngeal sensory testing by video recording


name: Flexible endoscopic evaluation of swallowing and laryngeal sensory testing by cine recording


name: Flexible endoscopic evaluation of swallowing and laryngeal sensory testing by video recording


name: Interpretation and report only of flexible endoscopic evaluation of swallowing and laryngeal sensory testing by cine recording


name: Interpretation and report only of flexible endoscopic evaluation of swallowing and laryngeal sensory testing by video recording


name: Evaluation of central auditory function with report, initial 60 minutes


name: Evaluation of central auditory function with report, each additional 15 minutes


name: Evaluation of auditory function for postopertative status of a surgically implanted device, first hour


name: Evaluation of auditory function for postoperative status of surgically implanted device, each additional 15 minutes


name: Evaluation of auditory function for surgically implanted device candidacy, each additional 15 minutes


name: Auditory rehabilitation for prelingual hearing loss


name: Auditory rehabilitation for postlingual hearing loss


name: Percutaneous transluminal coronary angioplasty into single major coronary artery


name: Percutaneous transluminal coronary angioplasty into single major coronary branch(es)


name: Percutaneous transluminal coronary atherectomy into single major coronary artery


name: Percutaneous transluminal coronary atherectomy into single major coronary branch(es)


name: Percutaneous transluminal coronary atherectomy with angioplasty into single major coronary artery


name: Percutaneous transluminal coronary atherectomy with angioplasty into single major coronary branch(es)


name: Percutaneous transluminal coronary atherectomy with angioplasty and insertion of stent into single major coronary artery


name: Percutaneous transluminal coronary atherectomy with angioplasty and insertion of stent into single major coronary branch(es)


name: Percutaneous transluminal coronary atherectomy with insertion of stent into single major coronary artery


name: Percutaneous transluminal coronary atherectomy with insertion of stent into single major coronary branch(es)


name: Intravascular ultrasound (IVUS) of coronary graft during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Intravascular ultrasound (IVUS) of coronary graft during diagnostic evaluation with imaging supervision, interpretation and report, initial vessel


name: Intravascular ultrasound (IVUS) of coronary graft during therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Intravascular ultrasound (IVUS) of coronary vessel during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Intravascular ultrasound (IVUS) of coronary vessel during diagnostic evaluation with imaging supervision, interpretation and report, initial vessel


name: Intravascular ultrasound (IVUS) of coronary vessel during therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Optical coherence tomography (OCT) of coronary graft during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Optical coherence tomography (OCT) of coronary graft during diagnostic evaluation with imaging supervision, interpretation and report, initial vessel


name: Optical coherence tomography (OCT) of coronary graft during therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Optical coherence tomography (OCT) of coronary vessel during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Optical coherence tomography (OCT) of coronary vessel during diagnostic evaluation with imaging supervision, interpretation and report, initial vessel


name: Optical coherence tomography (OCT) of coronary vessel during therapeutic intervention with imaging supervision, interpretation and report, initial vessel


name: Intravascular ultrasound (IVUS) of coronary graft during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Intravascular ultrasound (IVUS) of coronary graft during diagnostic evaluation with imaging supervision, interpretation and report, each additional vessel


name: Intravascular ultrasound (IVUS) of coronary graft during therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Intravascular ultrasound (IVUS) of coronary vessel during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Intravascular ultrasound (IVUS) of coronary vessel during diagnostic evaluation with imaging supervision, interpretation and report, each additional vessel


name: Intravascular ultrasound (IVUS) of coronary vessel during therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Optical coherence tomography (OCT) of coronary graft during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Optical coherence tomography (OCT) of coronary graft during diagnostic evaluation with imaging supervision, interpretation and report, each additional vessel


name: Optical coherence tomography (OCT) of coronary graft during therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Optical coherence tomography (OCT) of coronary vessel during diagnostic evaluation and therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: Optical coherence tomography (OCT) of coronary vessel during diagnostic evaluation with imaging supervision, interpretation and report, each additional vessel


name: Optical coherence tomography (OCT) of coronary vessel during therapeutic intervention with imaging supervision, interpretation and report, each additional vessel


name: External elective electrical conversion of arrhythmia


name: Internal elective electrical conversion of arrhythmia


name: Routine electrocardiogram (ECG) with interpretation and report, 12 or more leads


name: Tracing only of routine electrocardiogram (ECG), 12 or more leads


name: Interpretation and report only of routine electrocardiogram (ECG), 12 or more leads


name: Cardiovascular stress test with supervision, interpretation, and report


name: Cardiovascular stress test with supervision


name: Tracing only of cardiovascular stress test with supervision


name: Interpretation and report only of cardiovascular stress test


name: Rhythm electrocardiogram (ECG) with interpretation and report, 1-3 leads


name: Tracing only of rhythm electrocardiogram (ECG), 1-3 leads


name: Noninvasive upper extremity arterial pressure waveform analysis with assessment of central arterial pressure, interpretation, and report


name: Recording, scanning analysis with report, other qualified health care professional review and interpretation of external electrocardiographic recording up to 48 hours by continuous rhythm recording and storage


name: Other qualified health care professional review and interpretation of external electrocardiographic recording up to 48 hours by continuous rhythm recording and storage


name: Other qualified health care professional review and interpretation with report of external mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis, and greater than 24 hours of accessible electrocardiogram (ECG) data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days


name: Physician review and interpretation with report of external mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis, and greater than 24 hours of accessible electrocardiogram (ECG) data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days


name: Technical support for connection and patient instructions for use, attended surveillance for up to 30 days, analysis and other qualified health care professional prescribed transmission of daily and emergent data reports of external mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis, and greater than 24 hours of accessible electrocardiogram (ECG) data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center


name: Technical support for connection and patient instructions for use, attended surveillance for up to 30 days, analysis and physician prescribed transmission of daily and emergent data reports of external mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis, and greater than 24 hours of accessible electrocardiogram (ECG) data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center


name: External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation


name: Recording, scanning analysis with report, review and interpretation for external electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)


name: Connection and recording for external electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; scanning analysis with report


name: Scanning analysis and report for external electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation


name: Review and interpretation for external electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation


name: Heart rhythm recording for more than 7 days up to 15 days by continuous rhythm recording and storage, with review and interpretation


name: Recording, scanning analysis with report, review and interpretation for external electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)


name: Connection and initial recording for external electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; scanning analysis with report


name: Scanning analysis and report for external electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage


name: External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation


name: Review and interpretation for external electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage


name: Transmission, other qualified health care professional review and interpretation of external patient and auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Transmission, other qualified health care professional review and interpretation of external patient with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Transmission, physician review and interpretation of external patient and auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Transmission, physician review and interpretation of external patient with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Recording of external patient and auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Recording of external patient with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Transmission and analysis of external patient and auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Transmission and analysis of external patient with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Other qualified health care professional review and interpretation of external patient and auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Other qualified health care professional review and interpretation of external patient with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Physician review and interpretation of external patient and auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Physician review and interpretation of external patient with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring


name: Signal-averaged electrocardiography (SAECG), with electrocardiogram (ECG)


name: Programming device evaluation and adjustment of implantable subcutaneous lead defibrillator system with other qualified health care professional analysis, reviews, and report


name: Programming device evaluation in person of leadless pacemaker system in single chamber of heart with iterative adjustment, analysis, review, and report by other qualified health care professional


name: Programming device evaluation in person of leadless pacemaker system in single chamber of heart with iterative adjustment, analysis, review, and report by physician


name: Programming device evaluation of single lead pacemaker system in person with iterative adjustment, analysis, review, and report by other qualified health care professional


name: Programming device evaluation of single lead pacemaker system in person with iterative adjustment, analysis, review, and report by physician


name: Programming device evaluation in person with iterative adjustment of the implantable device with other qualified health care professional analysis, review, and report for dual lead pacemaker system


name: Programming device evaluation in person with iterative adjustment of the implantable device with other qualified health care professional analysis, review, and report for multiple lead pacemaker system


name: Programming device evaluation in person with iterative adjustment of the implantable device with other qualified health care professional analysis, review, and report for single lead implantable cardioverter-defibrillator system


name: Programming device evaluation in person with iterative adjustment of the implantable device with other qualified health care professional analysis, review, and report for dual lead implantable cardioverter-defibrillator system


name: Programming device evaluation in person with iterative adjustment of the implantable device with other qualified health care professional analysis, review, and report for multiple lead implantable cardioverter-defibrillator system


name: Programming device evaluation in person of subcutaneous cardiac rhythm monitor system with iterative adjustment, analysis, review, and report by other qualified health care professional


name: Programming device evaluation in person of subcutaneous cardiac rhythm monitor system with iterative adjustment, analysis, review, and report by physician


name: Evaluation of implantable subcutaneous lead defibrillator system with analysis, review, and report performed by other qualified health care professional


name: Evaluation of implantable subcutaneous lead defibrillator system with analysis, review, and report performed by physician


name: Interrogation device evaluation in person of dual lead pacemaker system with analysis, review, and report by other qualified health care professional


name: Interrogation device evaluation in person of dual lead pacemaker system with analysis, review, and report by physician


name: Interrogation device evaluation in person of multiple lead pacemaker system with analysis, review, and report by other qualified health care professional


name: Interrogation device evaluation in person of multiple lead pacemaker system with analysis, review, and report by physician


name: Interrogation device evaluation in person of single lead pacemaker system with analysis, review, and report by other qualified health care professional


name: Interrogation device evaluation in person of single lead pacemaker system with analysis, review, and report by physician


name: Interrogation device evaluation in person with other qualified health care professional analysis, review, and report, includes connection, recording, and disconnection per patient encounter for dual lead implantable cardioverter-defibrillator system, with analysis of heart rhythm derived data elements


name: Interrogation device evaluation in person with other qualified health care professional analysis, review, and report, includes connection, recording, and disconnection per patient encounter for multiple lead implantable cardioverter-defibrillator system, with analysis of heart rhythm derived data elements


name: Interrogation device evaluation in person with other qualified health care professional analysis, review, and report, includes connection, recording, and disconnection per patient encounter for single lead implantable cardioverter-defibrillator system, with analysis of heart rhythm derived data elements


name: Interrogation device evaluation in person with physician analysis, review, and report, includes connection, recording, and disconnection per patient encounter for dual lead implantable cardioverter-defibrillator system, with analysis of heart rhythm derived data elements


name: Interrogation device evaluation in person with physician analysis, review, and report, includes connection, recording, and disconnection per patient encounter for multiple lead implantable cardioverter-defibrillator system, with analysis of heart rhythm derived data elements


name: Interrogation device evaluation in person with physician analysis, review, and report, includes connection, recording, and disconnection per patient encounter for single lead implantable cardioverter-defibrillator system, with analysis of heart rhythm derived data elements


name: Interrogation device evaluation in person of implantable cardiovascular monitor system with analysis, review, and report, with analysis of multiple recorded physiologic cardiovascular data elements from internal and external sensors, by other qualified health care professional


name: Interrogation device evaluation in person of implantable cardiovascular monitor system with analysis, review, and report, with analysis of multiple recorded physiologic cardiovascular data elements from internal and external sensors, by physician


name: Interrogation device evaluation in person of implantable cardiovascular monitor system with analysis, review, and report, with analysis of single recorded physiologic cardiovascular data element from internal and external sensors, by other qualified health care professional


name: Interrogation device evaluation in person of implantable cardiovascular monitor system with analysis, review, and report, with analysis of single recorded physiologic cardiovascular data element from internal and external sensors, by physician


name: Interrogation device evaluation in person of subcutaneous cardiac rhythm monitor system with analysis, review, and report, with analysis of heart rhythm derived data, by other qualified health care professional


name: Interrogation device evaluation in person of subcutaneous cardiac rhythm monitor system with analysis, review, and report, with analysis of heart rhythm derived data, by physician


name: Interrogation device evaluation in person with other qualified health care professional analysis, review, and report, includes connection, recording, and disconnection per patient encounter of wearable defibrillator system


name: Remote monitoring of wireless pulmonary artery pressure sensor for up to 30 days with interpretation, trend analysis, and report by other qualified health care professional


name: Remote monitoring of wireless pulmonary artery pressure sensor for up to 30 days with interpretation, trend analysis, and report by physician


name: Periprocedural device evaluation in person and programming of dual lead pacemaker system with analysis, review, and report by other qualified health care professional


name: Periprocedural device evaluation in person and programming of dual lead pacemaker system with analysis, review, and report by physician


name: Periprocedural device evaluation in person and programming of multiple lead pacemaker system with analysis, review, and report by other qualified health care professional


name: Periprocedural device evaluation in person and programming of multiple lead pacemaker system with analysis, review, and report by physician


name: Periprocedural device evaluation in person of single lead pacemaker system with programming, analysis, review, and report by other qualified health care professional


name: Periprocedural device evaluation in person of single lead pacemaker system with programming, analysis, review, and report by physician


name: Periprocedural device evaluation in person and programming of device system parameters before or after a surgery, procedure, or test with other qualified health care professional analysis, review, and report for dual lead implantable cardioverter-defibrillator system


name: Periprocedural device evaluation in person and programming of device system parameters before or after a surgery, procedure, or test with other qualified health care professional analysis, review, and report for multiple implantable cardioverter-defibrillator system


name: Periprocedural device evaluation in person and programming of device system parameters before or after a surgery, procedure, or test with other qualified health care professional analysis, review, and report for single lead implantable cardioverter-defibrillator system


name: Periprocedural device evaluation in person and programming of device system parameters before or after a surgery, procedure, or test with physician analysis, review, and report for dual lead implantable cardioverter-defibrillator system


name: Periprocedural device evaluation in person and programming of device system parameters before or after a surgery, procedure, or test with physician analysis, review, and report for multiple implantable cardioverter-defibrillator system


name: Periprocedural device evaluation in person and programming of device system parameters before or after a surgery, procedure, or test with physician analysis, review, and report for single lead implantable cardioverter-defibrillator system


name: Transtelephonic rhythm strip pacemaker evaluations of dual lead pacemaker system, with recording up to 90 days with and without magnet application with other qualified health care professional analysis, review, and reports


name: Transtelephonic rhythm strip pacemaker evaluations of dual lead pacemaker system, with recording up to 90 days with and without magnet application with physician analysis, review, and reports


name: Transtelephonic rhythm strip pacemaker evaluations of multiple lead pacemaker system, with recording up to 90 days with and without magnet application with other qualified health care professional analysis, review, and reports


name: Transtelephonic rhythm strip pacemaker evaluations of multiple lead pacemaker system, with recording up to 90 days with and without magnet application with physician analysis, review, and reports


name: Transtelephonic rhythm strip pacemaker evaluations of single lead pacemaker system, with recording up to 90 days with and without magnet application with other qualified health care professional analysis, review, and reports


name: Transtelephonic rhythm strip pacemaker evaluations of single lead pacemaker system, with recording up to 90 days with and without magnet application with physician analysis, review, and reports


name: Remote interrogation device evaluation of dual lead pacemaker system with interim analysis, reviews, and report by other qualified health care professional


name: Remote interrogation device evaluation of dual lead pacemaker system with interim analysis, reviews, and report by physician


name: Remote interrogation device evaluation of multiple lead pacemaker system with interim analysis, reviews, and report by other qualified health care professional


name: Remote interrogation device evaluation of multiple lead pacemaker system with interim analysis, reviews, and report by physician


name: Remote interrogation device evaluation of single lead pacemaker system with interim analysis, reviews, and report by other qualified health care professional


name: Remote interrogation device evaluation of single lead pacemaker system with interim analysis, reviews, and report by physician


name: Remote interrogation device evaluation up to 90 days of dual lead implantable cardioverter-defibrillator system with interim other qualified health care professional analysis, reviews, and reports


name: Remote interrogation device evaluation up to 90 days of dual lead implantable cardioverter-defibrillator system with interim physician analysis, reviews, and reports


name: Remote interrogation device evaluation up to 90 days of multiple lead implantable cardioverter-defibrillator system with interim other qualified health care professional analysis, reviews, and reports


name: Remote interrogation device evaluation up to 90 days of multiple lead implantable cardioverter-defibrillator system with interim physician analysis, reviews, and reports


name: Remote interrogation device evaluation up to 90 days of single lead implantable cardioverter-defibrillator system with interim other qualified health care professional analysis, reviews, and reports


name: Remote interrogation device evaluation up to 90 days of single lead implantable cardioverter-defibrillator system with interim physician analysis, reviews, and reports


name: Remote interrogation device evaluation up to 90 days of dual lead pacemaker system with remote data acquisition, receipt of transmissions and technician review, technical support, and distribution of results


name: Remote interrogation device evaluation up to 90 days of implantable cardioverter-defibrillator system with remote data acquisition, receipt of transmissions and technician review, technical support, and distribution of results